Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

2015 ◽  
Vol 16 (6) ◽  
pp. 704-715 ◽  
Author(s):  
Maria Corinna A Palanca-Wessels ◽  
Myron Czuczman ◽  
Gilles Salles ◽  
Sarit Assouline ◽  
Laurie H Sehn ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Lymphocytic Leukaemia ◽  
Phase 1 ◽  
Antibody Drug Conjugate ◽  
Phase 1 Study ◽  
Drug Conjugate ◽  
Non Hodgkin Lymphoma ◽  
Antibody Drug

Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

2022 ◽  
pp. clincanres.3261.2021
Author(s):  
Alex F. Herrera ◽  
Manish R. Patel ◽  
John M. Burke ◽  
Ranjana Advani ◽  
Bruce D. Cheson ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Dose Escalation ◽  
Phase 1 ◽  
Antibody Drug Conjugate ◽  
Dose Escalation Study ◽  
Drug Conjugate ◽  
Non Hodgkin Lymphoma ◽  
Antibody Drug

scholarly journals P2.13-43 Phase 1 Study of the Anti-HER3 Antibody Drug Conjugate U3-1402 in Metastatic or Unresectable EGFR-Mutant NSCLC

2018 ◽  
Vol 13 (10) ◽  
pp. S815-S816
Author(s):  
P. Jänne ◽  
H. Yu ◽  
M. Johnson ◽  
C. Steuer ◽  
M. Vigliotti ◽  
...  
Keyword(s):  
Phase 1 ◽  
Antibody Drug Conjugate ◽  
Phase 1 Study ◽  
Drug Conjugate ◽  
Egfr Mutant ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document